← back to search

David A. Price

Pfizer (United States) · US
Area of research
Endocrinology, Diabetes and Metabolism · Surgery
Research interest
Research interests include Diabetes Management and Research, Growth Hormone and Insulin-like Growth Factors, Hyperglycemia and glycemic control in critically ill and hospitalized patients, and Diabetes Treatment and Management.
h-index
41
citations
6,752
works
138
NIH funding
primary concept
Medicine
email

Recent publications

Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin
JAMA 2021cited by 477position: middledoi
The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin
Diabetes Care 2021cited by 74position: middledoi
Episodic Real-Time CGM Use in Adults with Type 2 Diabetes: Results of a Pilot Randomized Controlled Trial.
2021cited by 56position: contributordoi
Magnitude of Glycemic Improvement in Patients with Type 2 Diabetes Treated with Basal Insulin: Subgroup Analyses from the MOBILE Study
Diabetes Technology & Therapeutics 2021cited by 29position: middledoi
Earlier Detection of GDM Via OGTT: Is It Helpful?
The Journal of Clinical Endocrinology & Metabolism 2020cited by 5position: contributordoi
Baseline Glycated Hemoglobin Values Predict the Magnitude of Glycemic Improvement in Patients with Type 1 and Type 2 Diabetes: Subgroup Analyses from the DIAMOND Study Program
Diabetes Technology & Therapeutics 2018cited by 36position: lastdoi
Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections
JAMA 2017cited by 1,139position: middledoi
Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections
Annals of Internal Medicine 2017cited by 608position: middledoi
How Patients With Type 1 Diabetes Translate Continuous Glucose Monitoring Data into Diabetes Management Decisions
Endocrine Practice 2015cited by 62position: middledoi

Grants

Molecular and Functional Characterization of Neuronal FMRFamide-Activated Channels
NSF9810804$75,0001998–2000PIRePORTER

Frequent collaborators

Roy W. Beck · Diabetes Australia3 papers (2017–2021)Craig Kollman · Diabetes Australia2 papers (2017–2017) · 2 papers (2020–2021)Richard M. Bergenstal · Systems, Applications & Products in Data Processing (United Kingdom)2 papers (2017–2017)Janet B. McGill · University of Colorado Denver2 papers (2017–2017)Stacie Haller · Joslin Diabetes Center2 papers (2017–2017)Katrina J. Ruedy · Jaeb Center for Health Research2 papers (2017–2017)Davida Kruger · Kruger (Canada)2 papers (2017–2017)Andrew Ahmann · Baylor Scott & White Health2 papers (2017–2017)Tonya D. Riddlesworth · Jaeb Center for Health Research2 papers (2017–2017)William H. Polonsky · Sansum Diabetes Research Institute2 papers (2017–2017)Elena Toschi · Harvard University2 papers (2017–2017)Stephen Aronoff · Temple University1 papers (2017–2017)Georgia M. Davis · Emory University1 papers (2021–2021)Christopher G. Parkin · Nevada State University1 papers (2018–2018)Steven V. Edelman · University of California San Diego1 papers (2015–2015)Jeremy Pettus · University of Colorado Denver1 papers (2015–2015)Howard Wolpert · Boston University1 papers (2017–2017)Peter Calhoun · Jaeb Center for Health Research1 papers (2021–2021)Ronnie Aronson · LMC Diabetes & Endocrinology (Canada)1 papers (2017–2017)